Clin2
NCT06521944Possibly a fitRecruiting

RSV vaccine safety registry for pregnant people

Respiratory Syncytial Virus (RSV)

Treatments studied

Part of Infections, Lungs & breathing clinical trials.

This registry follows pregnant people who received an RSV vaccine during a specific window (32 to 36 weeks) to monitor safety. If you got the shot in that time, your information helps researchers understand how well the vaccine works in pregnancy.

Summary written for real people, not researchers, by Clin2.

Phase
N/A
Enrollment
2,062 people
Ages
18 years to 50 years
Study type
Observational

Who can take part

  • You live in the United States.
  • You are between 18 and 50 years old.
  • You are at least 32 weeks pregnant (gestational age).
  • You received an RSV vaccine between 32 weeks and 36 weeks, 6 days of pregnancy.
  • You are not pregnant with more than one baby (like twins or triplets).

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07492706Not yet recruiting· Phase 1
RSV vaccine study for healthy women aged 18-49

This trial tests a new vaccine (MKK900) to see if it is safe and works well in healthy adult women. It is designed to protect against RSV, a common virus that can be serious in newborns and older adults. The vaccine is being developed for use during pregnancy to pass protection to babies.

Botany, New South Wales
NCT07618325Not yet recruiting
Testing immune response to a new RSV vaccine

This study tests how your body's immune system responds to a new respiratory syncytial virus (RSV) vaccine. RSV is a common virus that causes respiratory infections, especially in older adults. The vaccine may help protect you from RSV disease.

NCT07653100Recruiting· Phase 3
RSV vaccine study for adults with chronic conditions

This study tests an RSV vaccine in adults aged 18 and older, especially those with chronic health issues like heart or lung disease. It aims to see how safe and effective the vaccine is at preventing RSV infections.

Visakhapatnam, Andhra Pradesh
NCT07543380Recruiting· Phase 3
RSV vaccine safety and immune response in high-risk adults

This study tests a new RSV vaccine designed to protect adults with chronic health conditions from severe RSV disease (a respiratory infection). Researchers will monitor how safe the vaccine is and how well your immune system responds to it.

Tsuchiura, Ibaraki
NCT07272434Recruiting· Phase 3
RSV vaccine trial for adults 60 and older

This trial tests a new RSV vaccine for people aged 60 and above. RSV is a common virus that can cause serious breathing problems in older adults. The study will see if the vaccine is safe and helps protect you from RSV.

Guangzhou, Guangdong
NCT06955728Recruiting· Phase 3
RSV vaccine in pregnancy to protect babies

This study tests an approved RSV vaccine given to pregnant women. The goal is to see if it safely protects their babies from severe RSV lung infections during the first months of life.

Kintampo, Bono East

Hear when a new Respiratory Syncytial Virus (RSV) trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.